Performance of FDG PET/CT in postoperative colorectal cancer patients with a suspected recurrence and a normal CEA level

Nuclear Medicine Communications

Volumn 31, Issue 6, 2010, Pages 576-582

  Lee, Jai Hyuen ^a   Park, Seok Gun ^a   Jee, Keum Nahn ^a   Park, Dong Guk ^a   Namgung, Hwan ^a   Song, Il Han ^a  

^a Dankook University   (South Korea)

Author keywords

CEA; Colorectal cancer; PET CT; Recurrence

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER RECURRENCE; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE COMPLICATION; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOEMBRYONIC ANTIGEN; COLORECTAL NEOPLASMS; ENDOSCOPY; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; PHYSICAL EXAMINATION; POSITRON-EMISSION TOMOGRAPHY; POSTOPERATIVE PERIOD; RECURRENCE; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 77951769485     PISSN: 01433636     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNM.0b013e32833845b7     Document Type: Article

References (24)

1. Ministry For Health, Welfare and Family Affairs. Annual report of the central cancer registry in Korea, 2005.
2. Flamen P, Stroobants S, Van Cutsem E, Dupont P, Bormans G, De Vadder N, et al. Additional value of whole-body positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose in recurrent colorectal cancer. J Clin Oncol 1999; 17:894-901.
3. Kalff V, Hicks RJ, Ware RE, Hogg A, Binns D, McKenzie AF. The clinical impact of (18)F-FDG PET in patients with suspected or confirmed recurrence of colorectal cancer: a prospective study. J Nucl Med 2002; 43:492-499.
4. Reiter W, Stieber P, Reuter C, Nagel D, Lau-Werner U, Lamerz R. Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer. Anticancer Res 2000; 20:5195-5198.
5. Li Destri G, Di Cataldo A, Puleo S. Colorectal cancer follow-up: useful or useless? Surg Oncol 2006; 15:1-12.
6. Minton JP, Hoehn JL, Gerber DM, Horsley JS, Connolly DP, Salwan F, et al. Results of a 400-patient carcinoembryonic antigen second-look colorectal cancer study. Cancer 1985; 55:1284-1290.
7. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Tangen C. An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer. JAMA 1993; 270:943-947.
8. Wedell J, Meier zu Esssen P, Luu TH, Fiedler R, van Calker H, Koldowski P, et al. A retrospective study of serial CEA determinations in the early detection of recurrent colorectal cancer. Dis Colon Rectum 1981; 24:618-621.
9. Faneyte IF, Dresen RC, Edelbroek MA, Nieuwenhuijzen GA, Rutten HJ. Pre-operative staging with positron emission tomography in patients with pelvic recurrence of rectal cancer. Dig Surg 2008; 25:202-207.
10. Kitajima K, Murakami K, Yamasaki E, Domeki Y, Tsubaki M, Sunagawa M, et al. Performance of integrated FDG PET/contrast-enhanced CT in the diagnosis of recurrent colorectal cancer: comparison with integrated FDG PET/non-contrast- enhanced CT and enhanced CT. Eur J Nucl Med Mol Imaging 2009; 36:1388-1396.
11. Schiepers C, Penninckx F, De Vadder N, Merckx E, Mortelmans L, Bormans G, et al. Contribution of PET in the diagnosis of recurrent colorectal cancer: comparison with conventional imaging. Eur J Surg Oncol 1995; 21:517-522.
12. Sarikaya I, Bloomston M, Povoski SP, Zhang J, Hall NC, Knopp MV, et al. FDG PET scan in patients with clinically and/or radiologically suspicious colorectal cancer recurrence but normal CEA. World J Surg Oncol 2007; 5:64-72.
13. Votrubova J, Belohlavek O, Jaruskova M, Oliverius M, Lohynska R, Trskova K, et al. The role of FDG PET/CT in the detection of recurrent colorectal cancer. Eur J Nucl Med Mol Imaging 2006; 33:779-784.
14. Takeuchi O, Saito N, Koda K, Sarashina H, Nakajima N. Clinical assessment of positron emission tomography for the diagnosis of local recurrence in colorectal cancer. Br J Surg 1999; 86:932-937.
15. Even-Sapir E, Parag Y, Lerman H, Gutman M, Levine C, Rabau M, et al. Detection of recurrence in patients with rectal cancer: PET/CT after abdominoperineal or anterior resection. Radiology 2004; 232:815-822.
16. Chen LB, Tong JL, Song HZ, Zhu H, Wang YC. (18)F-DG PET/CT in detection of recurrence and metastasis of colorectal cancer. World J Gastroenterol 2007; 13:5025-5029.
17. Cohade C, Osman M, Leal J,Wahl RL. Direct comparison of (18)F-FDG PET and PET/CT in patients with colorectal carcinoma. J Nucl Med 2003; 44:1797-1803.
18. Flamen P, Hoekstra OS, Homans F, Van Cutsem E, Maes A, Stroobants S, et al. Unexplained rising carcinoembryonic antigen (CEA) in the postoperative surveillance of colorectal cancer: the utility of positron emission tomography (PET). Eur J Cancer 2001; 37:862-869.
19. Flanagan FL, Dehdashti F, Ogunbiyi OA, Kodner IJ, Siegel BA. Utility of FDG PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer. Ann Surg 1998; 227:319-323.
20. Maldonado A, Sancho F, Cerdan J, Lozano A, Mohedano N, Jimenez J, et al. 16.FDG PET in the detection of recurrence in colorectal cancer based on rising CEA level. Experience in 72 patients. Clin Positron Imaging 2000; 3:170.
21. Shen YY, Liang JA, Chen YK, Tsai CY, Kao CH. Clinical impact of 18F-FDG PET in the suspicion of recurrent colorectal cancer based on asymptomatically elevated serum level of carcinoembryonic antigen (CEA) in Taiwan. Hepatogastroenterology 2006; 53:348-350.
22. Hara M, Kanemitsu Y, Hirai T, Komori K, Kato T. Negative serum carcinoembryonic antigen has insufficient accuracy for excluding recurrence from patients with Dukes C colorectal cancer: analysis with likelihood ratio and posttest probability in a follow-up study. Dis Colon Rectum 2008; 51:1675-1680.
23. Tan E, Gouvas N, Nicholls RJ, Ziprin P, Xynos E, Tekkis PP. Diagnostic precision of carcinoembryonic antigen in the detection of recurrence of colorectal cancer. Surg Oncol 2009; 18:15-24.
24. Morita S, Nomura T, Fukushima Y, Morimoto T, Hiraoka N, Shibata N. Does serum CA19-9 play a practical role in the management of patients with colorectal cancer? Dis Colon Rectum 2004; 47:227-232.